GoAI
Get started
ARS Pharmaceuticals, Inc. logo

ARS Pharmaceuticals, Inc.

SPRY

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$5.505

$0.00 · 0.00%

Aug 21, 4:00 PM ET

SPRY company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

42

Fair Value

Momentum

30

Weakening

Sentiment

36

Bearish

Risk resilience

36

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

ARS Pharmaceuticals, Inc. specializes in creating ARS-1, an innovative intranasal epinephrine spray utilizing advanced absorption technology. This product serves as a crucial intervention for individuals and their households who are susceptible to life-threatening allergic reactions caused by food, pharmaceuticals, or insect stings. Among its offerings is Neffy, a low-dose version of its intranasal epinephrine nasal spray. Established in 2015, the firm operates out of San Diego, California.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Donn Casale
Listed since
Dec 4, 2020
Employees
163

Market position

Day range

Current $5.505

52-week range

Current $5.505

Open
$5.515
Previous close
$5.505
Volume
1.27M
0.64× average
Average volume
1.99M
Average daily volume
Market cap
546.66M USD
Beta
0.88
Market reference 1
50-day average
$7.258
-24.15% below average
200-day average
$8.7017
-36.74% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
1.2B USD
EV / EBITDA
-7.19×
Earnings yield
-14.92%
Free cash flow yield
-14.91%

Profitability & efficiency

Return on equity
-149.92%
Return on assets
-52.28%
Return on invested capital
-62.17%

Financial health

Current ratio
7.28×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends22617%-67450%-157517%-247583%Gross margin, FY2021: 96.13%Gross margin, FY2022: -1200.91%Gross margin, FY2023: 100.00%Gross margin, FY2024: 76.94%Gross margin, FY2025: 75.77%Operating margin, FY2021: -353.32%Operating margin, FY2022: -2698.78%Operating margin, FY2023: -225066.67%Operating margin, FY2024: -3.46%Operating margin, FY2025: -212.92%Net margin, FY2021: -367.65%Net margin, FY2022: -2635.41%Net margin, FY2023: -181216.67%Net margin, FY2024: 8.97%Net margin, FY2025: -203.25%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 96.13%. Gross margin FY2022 -1200.91%. Gross margin FY2023 100.00%. Gross margin FY2024 76.94%. Gross margin FY2025 75.77%. Operating margin FY2021 -353.32%. Operating margin FY2022 -2698.78%. Operating margin FY2023 -225066.67%. Operating margin FY2024 -3.46%. Operating margin FY2025 -212.92%. Net margin FY2021 -367.65%. Net margin FY2022 -2635.41%. Net margin FY2023 -181216.67%. Net margin FY2024 8.97%. Net margin FY2025 -203.25%.

Income trends

Revenue

84.28M USD-5.46%

Operating income

−179.45M USD-5720.56%

Net income

−171.3M USD−179.3M USD
Income trends across reported periods116.01M USD8.57M USD−98.87M USD−206.31M USDRevenue, FY2021: 5.51M USDRevenue, FY2022: 1.32M USDRevenue, FY2023: 30K USDRevenue, FY2024: 89.15M USDRevenue, FY2025: 84.28M USDOperating income, FY2021: −19.45M USDOperating income, FY2022: −35.52M USDOperating income, FY2023: −67.52M USDOperating income, FY2024: −3.08M USDOperating income, FY2025: −179.45M USDNet income, FY2021: −20.24M USDNet income, FY2022: −34.68M USDNet income, FY2023: −54.37M USDNet income, FY2024: 8M USDNet income, FY2025: −171.3M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 5.51M USD. Revenue FY2022 1.32M USD. Revenue FY2023 30K USD. Revenue FY2024 89.15M USD. Revenue FY2025 84.28M USD. Operating income FY2021 −19.45M USD. Operating income FY2022 −35.52M USD. Operating income FY2023 −67.52M USD. Operating income FY2024 −3.08M USD. Operating income FY2025 −179.45M USD. Net income FY2021 −20.24M USD. Net income FY2022 −34.68M USD. Net income FY2023 −54.37M USD. Net income FY2024 8M USD. Net income FY2025 −171.3M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue84.28M USD89.15M USD30K USD1.32M USD5.51M USD
Cost of goods sold20.42M USD20.56M USD—17.12M USD213K USD
Gross profit63.86M USD68.59M USD30K USD−15.8M USD5.29M USD
Research and development13.18M USD19.58M USD20.27M USD18.38M USD20.27M USD
Selling, general, and administrative230.12M USD—47.28M USD18.66M USD4.69M USD
Operating expenses243.3M USD71.68M USD67.55M USD19.71M USD24.75M USD
Interest income10.67M USD———800K USD
Interest expense2.6M USD———106K USD
Depreciation and amortization1.37M USD79K USD73K USD319K USD213K USD
Operating income−179.45M USD−3.08M USD−67.52M USD−35.52M USD−19.45M USD
Net income−171.3M USD8M USD−54.37M USD−34.68M USD−20.24M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
18%
2 beats, 6 misses, 3 met estimates
Average EPS surprise
+123.26%
11 comparable reports
Latest EPS result
-0.63
Estimate -0.48 · Miss by 31.89%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.610.17-0.28-0.72Q1 '25BeatQ2 '25MetQ3 '25MissQ4 '25MissQ1 '26MetQ2 '26MissQ3 '26MissQ4 '26Estimate
Q1 2025, reported Mar 20, 2025: actual 0.52, estimate -0.04, surprise +1400.00%, Beat. Q2 2025, reported May 14, 2025: actual -0.35, estimate -0.35, surprise 0.00%, Met estimate. Q3 2025, reported Aug 13, 2025: actual -0.46, estimate -0.41, surprise -12.20%, Miss. Q4 2025, reported Nov 10, 2025: actual -0.52, estimate -0.45, surprise -15.56%, Miss. Q1 2026, reported Mar 9, 2026: actual -0.42, estimate -0.42, surprise 0.00%, Met estimate. Q2 2026, reported May 15, 2026: actual -0.61, estimate -0.53, surprise -15.09%, Miss. Q3 2026, reported Aug 13, 2026: actual -0.63, estimate -0.478, surprise -31.89%, Miss. Q4 2026, reported Nov 9, 2026: actual —, estimate -0.33, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates92.87M64.17M35.47M6.78MQ1 '25BeatQ2 '25MissQ3 '25MissQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 20, 2025: actual 86.58M USD, estimate 12.84M USD, surprise +574.41%, Beat. Q2 2025, reported May 14, 2025: actual 7.97M USD, estimate 14.71M USD, surprise -45.79%, Miss. Q3 2025, reported Aug 13, 2025: actual 15.72M USD, estimate 27.67M USD, surprise -43.21%, Miss. Q4 2025, reported Nov 10, 2025: actual 32.5M USD, estimate 25.58M USD, surprise +27.04%, Beat. Q1 2026, reported Mar 9, 2026: actual 28.1M USD, estimate 25.62M USD, surprise +9.69%, Beat. Q2 2026, reported May 15, 2026: actual 22.68M USD, estimate 22.2M USD, surprise +2.17%, Beat. Q3 2026, reported Aug 13, 2026: actual 33.66M USD, estimate 31.32M USD, surprise +7.46%, Beat. Q4 2026, reported Nov 9, 2026: actual —, estimate 44.84M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$25.50

363.22% upside
Past 12 months12-month forecastHigh $26.00Average $25.50Low $25.00

Rating distribution

10 ratings
Strong buy110%
Buy330%
Hold660%
Sell00%
Strong sell00%

Recent analyst actions

5 institutions
William BlairdowngradeOutperformMarket Perform

SPRY news

newsfilecorp.com

ROSEN, A LEADING LAW FIRM, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SPRY

New York, New York--(Newsfile Corp. - August 23, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) between March 9, 2026 and June…

Read source
newsfilecorp.com

SPRY INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ARS Pharmaceuticals To Contact Him Directly To Discuss Their Options If you purchased or acquired…

Read source
newsfilecorp.com

ROSEN, HIGHLY REGARDED INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SPRY

New York, New York--(Newsfile Corp. - August 21, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) between March 9, 2026 and June…

Read source
globenewswire.com

SPRY Investors Have Rights – If You Lost Money Investing in ARS Pharmaceuticals Inc. Contact Robbins LLP for Information Recovering Your Losses

SAN DIEGO, Aug. 21, 2026 (GLOBE NEWSWIRE) -- Robbins LLP reminds shareholders that a securities class action has been filed on behalf of all investors who purchased or otherwise acquired ARS Pharmaceuticals Inc. (NASDAQ:…

Read source
newsfilecorp.com

Kaplan Fox Alerts Investors of ARS Pharmaceuticals Inc. (SPRY) to a Pending Securities Class Action - Deadline is October 5, 2026

New York, New York--(Newsfile Corp. - August 21, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against ARS Pharmaceuticals Inc. ("ARS" or the "Company") (NASDAQ: SPRY) on behalf…

Read source
globenewswire.com

SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law

LOS ANGELES, Aug. 21, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ARS Pharmaceuticals, Inc. (“ARS” or…

Read source

SPRY peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding SPRY

Funds reporting this stock among their holdings, ordered by reported position size.

State Street SPDR S&P Biotech ETF logoState Street SPDR S&P Biotech ETFXBI
Market value
13.22M
Weight
0.12%
AUM
11.39B USD
Expense ratio
0.35%
Price / 1D
$165.73+1.44%
Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
8.98M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
8.72M
Weight
0.01%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
3.87M
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Russell 2000 Growth ETF logoiShares Russell 2000 Growth ETFIWO
Market value
3.18M
Weight
0.02%
AUM
15.16B USD
Expense ratio
0.24%
Price / 1D
$387.37+1.24%
iShares Biotechnology ETF logoiShares Biotechnology ETFIBB
Market value
2.56M
Weight
0.02%
AUM
10.75B USD
Expense ratio
0.44%
Price / 1D
$213.56+1.29%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
1.77M
Weight
0.01%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%
Schwab U.S. Small-Cap ETF logoSchwab U.S. Small-Cap ETFSCHA
Market value
1.71M
Weight
0.01%
AUM
23.1B USD
Expense ratio
0.03%
Price / 1D
$34.83+0.52%

Continue in GoAI

Research SPRY

research.disclaimer